Literature DB >> 27212206

TMEM5-associated dystroglycanopathy presenting with CMD and mild limb-girdle muscle involvement.

Guja Astrea1, Ilaria Pezzini1, Ester Picillo2, Rosa Pasquariello1, Francesca Moro1, Manuela Ergoli2, Paola D'Ambrosio2, Adele D'Amico3, Luisa Politano2, Filippo Maria Santorelli4.   

Abstract

The dystroglycanopathies, which are caused by reduced glycosylation of alpha-dystroglycan, are a heterogeneous group of neurodegenerative disorders characterized by variable brain and skeletal muscle involvement. Recently, mutations in TMEM5 have been described in severe dystroglycanopathies. We present the clinical, molecular and neuroimaging features of an Italian boy who had delayed developmental milestones with mild limb-girdle muscle involvement, bilateral frontotemporal polymicrogyria, moderate intellectual disability, and no cerebellar involvement. He also presented a cochlear dysplasia and harbored a reported mutation (p.A47Rfs*42) in TMEM5, detected using targeted next-generation sequencing. The relatively milder muscular phenotype and associated structural brain abnormalities distinguish this case from previously reported patients with severe dystroglycanopathies and expand the spectrum of TMEM5-associated disorders.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cochlear dysplasia; Congenital muscular dystrophy; Limb-girdle muscle weakness; Polymicrogyria; TMEM5

Mesh:

Substances:

Year:  2016        PMID: 27212206      PMCID: PMC4925463          DOI: 10.1016/j.nmd.2016.05.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


Introduction

The dystroglycanopathies are heterogeneous clinical conditions characterized by reduced glycosylation of alpha-dystroglycan (α-DG) in skeletal muscles [1]. Clinical presentations range from prenatal brain malformations to congenital muscular dystrophies (CMDs) with various combinations of ocular involvement and mental retardation, and late-onset limb-girdle muscular dystrophies (LGMDs) [1]. The list of disease-associated genes has grown rapidly with the advent of next-generation sequencing (NGS) technologies which can be combined with protein network analysis [2], and this has significantly expanded the spectrum of clinical phenotypes [3]. TMEM5 encodes a transmembrane protein thought to be involved in the glycosylation of dystroglycan [2]. Mutations in TMEM5 were initially described in three infants presenting congenital muscle hypotonia and severe brain malformations meeting the clinical diagnosis of Walker–Warburg syndrome (WWS)/muscle–eye–brain disease (MEB) [2], the most severe, rapidly lethal forms of CMD [1]. A study of an undiagnosed cohort of fetuses with cobblestone type II lissencephaly (cobblestone-LIS) [4], a peculiar brain malformation with characteristic MRI abnormalities, revealed five additional mutations. We herein expand the phenotypic spectrum of disorders associated with mutations in TMEM5, describing a patient who presented repeatedly elevated CK levels and mild limb-girdle muscular involvement, and whose NGS-based molecular testing disclosed an already reported variant.

Case report

This 13-year-old boy was born to non-consanguineous healthy parents at 38 weeks of gestation. At birth he presented with a low birth weight (2600 g), normal head circumference (36 cm) and respiratory distress. His neurodevelopment was globally delayed as he had achieved the sitting position at the age of 8 months and walked unaided at 23 months. A firstEEG recording, ordered by the general pediatrician because of developmental delay at the age of 14 months, showed polymorphic slow waves but no seizures. At the age of 3 years, medical examinations prior to surgery for undescended testis revealed elevated serum creatine kinase (CK) levels (2054 U/L, normal <190). Despite an improvement in his motor skills, due to speech and psychomotor therapy, the patient underwent a skeletal muscle biopsy at the age of 4 years because of persistently elevated CK levels (3227 U/L) and EMG features suggestive of a myopathy. Histochemistry showed a dystrophic pattern with abnormal variation in fiber size, necrosis and few scattered degenerative fibers, whereas immunofluorescent stains for dystrophin, merosin/laminin-a2 (300 kDa antibody) and sarcoglycans were normal (not shown). The glycosylated forms of α-DG were not analyzed because of lack of material. At the age of 5 years – when his weight was 24 kg (97° percentile), height 114 cm (85°), and head circumference 50 cm (50°) – a brain MRI showed bilateral frontotemporal polymicrogyria (Fig. 1A–C), abnormal signals in the frontoparietal white matter bilaterally, with a patchy, confluent appearance (Fig. 1D–F), a dysplastic cerebellar cortex, and small subcortical cerebellar cysts (Fig. 1G). Hypoplasia of the pons with a ventral cleft and a dilated and dysmorphic fourth ventricle (Fig. 1H), and also bilateral cochlear dysplasia (Fig. 1I), were also seen.
Fig. 1

Brain MRI in a patient with CMD carrying a mutation in TMEM5. (A–C) Coronal, axial and sagittal FSE T2-weighted images showing bilateral frontotemporal polymicrogyria (white arrow). (D, E) Axial FLAIR and (F) coronal FSE T2-weighted images revealing patchy, confluent frontoparietal white matter hyperintensities, bilaterally distributed (white arrow). In F as well as in G (axial T2-weighted image) cerebellar anomalies are evident. The latter include abnormal orientation of the cerebellar folia, an irregular gray matter-white matter junction (black arrows) and multiple small subcortical cysts in both cerebellar hemispheres (white arrow heads). In G the cleft in the ventral pons (note the black arrow head) and an enlarged and dysmorphic fourth ventricle (star) are also evident. (H) Sagittal T1-weighted image demonstrating hypoplasia of the pons (white arrow) and a mildly enlarged tectum (white arrow head). (I) Reconstruction of MIP 3D FIESTA image showing bilateral cochlear dysplasia, with fusion of the middle and apical cochlear turns, suggestive of Mondini-type deformity (white arrow). R, right; L, left.

The patient attended yearly neuromuscular follow-ups, and showed a stable clinical course. At the time of latest examination when he was age 13, his growth was normal but he revealed relatively mild symmetric proximal weakness: he was able to walk 10 m in 6 s, to run 10 m in 3.3 s, and to rise from the floor in 12 s. His forced vital capacity was 63% of normal values. Ocular and cardiac evaluations were normal and there were neither gait and trunk ataxia nor dysmetria and nystagmus. Neuropsychological assessment revealed a moderate mental delay with low verbal skills and slight deficits in attention, short term working memory, and problem solving. Consistently with the bilateral cochlear dysplasia observed on neuroimaging, brain auditory evoked potentials revealed mild hearing impairment, especially in the right ear. This case was included in a group of undiagnosed muscular dystrophy patients to be analyzed by Dystroplex, an extended NGS testing panel able to investigate, in a single tube, the coding regions of 93 genes linked to CMDs, LGMDs or related diseases (see supplementary Appendix). We detected the already described homozygous c.139delG:p.(A47Rfs*42) in TMEM5 [2]. The mutation was confirmed by Sanger sequencing and found to be heterozygous in the healthy parents. Two additional predicted deleterious variants [the heterozygous c.1654-6A>G in POMT2, described in a child with LGMD and low α-DG [5], and the novel c.1079A>G: p.(Y360C) in DOLK] were also detected in the patient and his father.

Discussion

To date, 12 patients harboring mutations in TMEM5 have been described. Two siblings carried the homozygous p.A47Rfs*42 mutation and had severe intellectual disability with autistic features, microcephaly, broad-based gait, 20-fold increased levels of serum CK, and a dystrophic pattern on muscle biopsy. In one case, neuroimaging revealed brainstem atrophy, dilated ventricles, widespread pachygyria and significant white matter changes [2]. A nonsense p.R340* was detected in the same study in an unrelated WWS newborn who had muscle hypotonia, right microphthalmia, bilateral opaque cornea, cranial ultrasound evidence of hydrocephalus, and occipital encephalocele, and died at the age of 22 months [2]. Lastly, nine fetuses in five families with cobblestone-LIS harbored different loss-of-function changes [4]. The present case report lies at the mildest end of the possible spectrum of TMEM5-associated disorders. Unlike previously reported cases carrying p.A47Rfs*42, our patient showed only mildly delayed achievement of motor milestones and neither signs of cerebellar involvement nor microcephaly; furthermore, he presented mild muscular weakness that involved the lower limb-girdle muscles but did not prevent him from running or using a bike, even though he tired quickly. The phenotype appeared severe on brain imaging, yet resulted in only moderate intellectual disability and the boy was able to attend school profitably without needing a support teacher. Our data offer a further example of the value of targeted NGS technologies in clinical settings. The striking differences with earlier TMEM5-related cases provide a further illustration of the fact that clinical presentation in the dystroglycanopathies cannot be explained solely by the specific gene mutation [6]. The question of whether other modifiers of the α-DG glycosylation pathway might have contributed to the milder course seen in our patient remains unanswered.
  6 in total

Review 1.  The ever-expanding spectrum of congenital muscular dystrophies.

Authors:  Eugenio Mercuri; Francesco Muntoni
Journal:  Ann Neurol       Date:  2012-07       Impact factor: 10.422

Review 2.  Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies.

Authors:  Francesco Muntoni; Silvia Torelli; Dominic J Wells; Susan C Brown
Journal:  Curr Opin Neurol       Date:  2011-10       Impact factor: 5.710

3.  Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly.

Authors:  Sandrine Vuillaumier-Barrot; Céline Bouchet-Séraphin; Malika Chelbi; Louise Devisme; Samuel Quentin; Steven Gazal; Annie Laquerrière; Catherine Fallet-Bianco; Philippe Loget; Sylvie Odent; Dominique Carles; Anne Bazin; Jacqueline Aziza; Alix Clemenson; Fabien Guimiot; Maryse Bonnière; Sophie Monnot; Christine Bole-Feysot; Jean-Pierre Bernard; Laurence Loeuillet; Marie Gonzales; Koryna Socha; Bernard Grandchamp; Tania Attié-Bitach; Férechté Encha-Razavi; Nathalie Seta
Journal:  Am J Hum Genet       Date:  2012-12-07       Impact factor: 11.025

4.  Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry.

Authors:  Lucas T Jae; Matthijs Raaben; Moniek Riemersma; Ellen van Beusekom; Vincent A Blomen; Arno Velds; Ron M Kerkhoven; Jan E Carette; Haluk Topaloglu; Peter Meinecke; Marja W Wessels; Dirk J Lefeber; Sean P Whelan; Hans van Bokhoven; Thijn R Brummelkamp
Journal:  Science       Date:  2013-03-21       Impact factor: 47.728

5.  Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.

Authors:  Katsiaryna Belaya; Pedro M Rodríguez Cruz; Wei Wei Liu; Susan Maxwell; Simon McGowan; Maria E Farrugia; Richard Petty; Timothy J Walls; Maryam Sedghi; Keivan Basiri; Wyatt W Yue; Anna Sarkozy; Marta Bertoli; Matthew Pitt; Robin Kennett; Andrew Schaefer; Kate Bushby; Matt Parton; Hanns Lochmüller; Jacqueline Palace; Francesco Muntoni; David Beeson
Journal:  Brain       Date:  2015-06-30       Impact factor: 13.501

6.  Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.

Authors:  Caroline Godfrey; Emma Clement; Rachael Mein; Martin Brockington; Janine Smith; Beril Talim; Volker Straub; Stephanie Robb; Ros Quinlivan; Lucy Feng; Cecilia Jimenez-Mallebrera; Eugenio Mercuri; Adnan Y Manzur; Maria Kinali; Silvia Torelli; Susan C Brown; Caroline A Sewry; Kate Bushby; Haluk Topaloglu; Kathryn North; Stephen Abbs; Francesco Muntoni
Journal:  Brain       Date:  2007-09-18       Impact factor: 13.501

  6 in total
  7 in total

1.  The Muscular Dystrophy Gene TMEM5 Encodes a Ribitol β1,4-Xylosyltransferase Required for the Functional Glycosylation of Dystroglycan.

Authors:  Hiroshi Manya; Yoshiki Yamaguchi; Motoi Kanagawa; Kazuhiro Kobayashi; Michiko Tajiri; Keiko Akasaka-Manya; Hiroko Kawakami; Mamoru Mizuno; Yoshinao Wada; Tatsushi Toda; Tamao Endo
Journal:  J Biol Chem       Date:  2016-10-12       Impact factor: 5.157

Review 2.  Roles, molecular mechanisms, and signaling pathways of TMEMs in neurological diseases.

Authors:  Qinghong Chen; Junlin Fang; Hui Shen; Liping Chen; Mengying Shi; Xianbao Huang; Zhiwei Miao; Yating Gong
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  A Novel Defined Hypoxia-Related Gene Signature for Prognostic Prediction of Patients With Ewing Sarcoma.

Authors:  Runyi Jiang; Jinbo Hu; Hongfei Zhou; Haifeng Wei; Shaohui He; Jianru Xiao
Journal:  Front Genet       Date:  2022-06-02       Impact factor: 4.772

Review 4.  Learning disabilities in neuromuscular disorders: a springboard for adult life.

Authors:  Guja Astrea; Roberta Battini; Sara Lenzi; Silvia Frosini; Silvia Bonetti; Elena Moretti; Silvia Perazza; Filippo M Santorelli; Chiara Pecini
Journal:  Acta Myol       Date:  2016-10

5.  B3GALNT2 mutations associated with non-syndromic autosomal recessive intellectual disability reveal a lack of genotype-phenotype associations in the muscular dystrophy-dystroglycanopathies.

Authors:  Reza Maroofian; Moniek Riemersma; Lucas T Jae; Narges Zhianabed; Marjolein H Willemsen; Willemijn M Wissink-Lindhout; Michèl A Willemsen; Arjan P M de Brouwer; Mohammad Yahya Vahidi Mehrjardi; Mahmoud Reza Ashrafi; Benno Kusters; Tjitske Kleefstra; Yalda Jamshidi; Mojila Nasseri; Rolph Pfundt; Thijn R Brummelkamp; Mohammad Reza Abbaszadegan; Dirk J Lefeber; Hans van Bokhoven
Journal:  Genome Med       Date:  2017-12-22       Impact factor: 11.117

6.  Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness.

Authors:  Katherine Johnson; Marta Bertoli; Lauren Phillips; Ana Töpf; Peter Van den Bergh; John Vissing; Nanna Witting; Shahriar Nafissi; Shirin Jamal-Omidi; Anna Łusakowska; Anna Kostera-Pruszczyk; Anna Potulska-Chromik; Nicolas Deconinck; Carina Wallgren-Pettersson; Sonja Strang-Karlsson; Jaume Colomer; Kristl G Claeys; Willem De Ridder; Jonathan Baets; Maja von der Hagen; Roberto Fernández-Torrón; Miren Zulaica Ijurco; Juan Bautista Espinal Valencia; Andreas Hahn; Hacer Durmus; Tracey Willis; Liwen Xu; Elise Valkanas; Thomas E Mullen; Monkol Lek; Daniel G MacArthur; Volker Straub
Journal:  Skelet Muscle       Date:  2018-07-30       Impact factor: 4.912

7.  Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study.

Authors:  Guja Astrea; Alessandro Romano; Corrado Angelini; Carlo Giuseppe Antozzi; Rita Barresi; Roberta Battini; Carla Battisti; Enrico Bertini; Claudio Bruno; Denise Cassandrini; Marina Fanin; Fabiana Fattori; Chiara Fiorillo; Renzo Guerrini; Lorenzo Maggi; Eugenio Mercuri; Federica Morani; Marina Mora; Francesca Moro; Ilaria Pezzini; Esther Picillo; Michele Pinelli; Luisa Politano; Anna Rubegni; Walter Sanseverino; Marco Savarese; Pasquale Striano; Annalaura Torella; Carlo Pietro Trevisan; Rosanna Trovato; Irina Zaraieva; Francesco Muntoni; Vincenzo Nigro; Adele D'Amico; Filippo M Santorelli
Journal:  Orphanet J Rare Dis       Date:  2018-09-26       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.